Table 1.
Population characteristics of matched sample by treatment group.
| Characteristic | All patients N = 5,430 N (%) | IMRT N = 2,715 N (%) | SBRT N = 2,715 N (%) | p-Values |
|---|---|---|---|---|
| Age | 0.4032 | |||
| <55 | 275 (5.1%) | 123 (4.5%) | 152 (5.6%) | |
| 55–59 | 518 (9.5%) | 260 (9.6%) | 258 (9.5%) | |
| 60–64 | 1,411 (25.9%) | 438 (16.1%) | 454 (16.7%) | |
| 65–69 | 1,276 (23.5%) | 715 (26.3%) | 696 (25.6%) | |
| 70–74 | 1,058 (19.5%) | 658 (24.2%) | 618 (22.8%) | |
| 75–90 | 1,058 (19.5%) | 521 (19.2%) | 537 (19.8%) | |
| Race | 0.4803 | |||
| Black | 597 (11.0%) | 281 (10.4%) | 316 (11.6%) | |
| Other | 79 (1.5%) | 38 (1.4%) | 41 (1.5%) | |
| Unknown | 40 (0.7%) | 20 (0.7%) | 20 (0.7%) | |
| White | 4,714 (86.8%) | 2,376 (87.5%) | 2,338 (86.1%) | |
| Insurance status | 0.9208 | |||
| Insurance status unknown | 59 (1.1%) | 31 (1.1%) | 28 (1.0%) | |
| Medicaid | 50 (0.9%) | 24 (0.9%) | 26 (1.0%) | |
| Medicare | 3,289 (60.6%) | 1,653 (60.9%) | 1,636 (60.3%) | |
| Not insured | 56 (1.0%) | 30 (1.1%) | 26 (1.0%) | |
| Other government | 52 (1.0%) | 23 (0.9%) | 29 (1.1%) | |
| Private insurance | 1,924 (35.4%) | 954 (35.1%) | 971 (35.7%) | |
| Patient residence | 0.5233 | |||
| Metropolitan | 4,894 (90.1%) | 2,442 (89.9%) | 2,452 (90.3%) | |
| Rural | 48 (0.9%) | 21 (0.8%) | 27 (1.0%) | |
| Urban | 488 (9.0%) | 252 (9.3%) | 236 (8.7%) | |
| Median household income (US$) | 0.0746 | |||
| <38,000 | 451 (8.3%) | 214 (7.9%) | 237 (8.7%) | |
| 38,000–47,999 | 773 (14.2%) | 394 (14.5%) | 379 (14.0%) | |
| 48,000–62,999 | 1,223 (22.5%) | 647 (23.8%) | 576 (21.2%) | |
| 63,000+ | 2,983 (54.9%) | 1,460 (53.8%) | 1,523 (56.1%) | |
| Charlson–Deyo comorbidity score | 0.0155 | |||
| 0 | 4,783 (88.1%) | 2,417 (89.0%) | 2,366 (87.2%) | |
| 1 | 555 (10.2%) | 247 (9.1%) | 308 (11.3%) | |
| 2 | 92 (1.7%) | 51 (1.9%) | 41 (1.5%) | |
| Facility type | 0.0026 | |||
| Academic/research program | 2,660 (49.0%) | 1,269 (46.7%) | 1,391 (51.2%) | |
| Community cancer program | 55 (1.0%) | 27 (1.0%) | 28 (1.0%) | |
| Comprehensive community program | 2,291 (42.2%) | 1,214 (44.7%) | 1,077 (39.7%) | |
| Integrated network cancer program | 424 (7.8%) | 205 (7.6%) | 219 (8.1%) | |
| Year of diagnosis | 0.5820 | |||
| 2004–2009 | 2,266 (41.7%) | 1,123 (41.4%) | 1,143 (42.1%) | |
| 2010–2013 | 3,164 (58.3%) | 1,592 (58.6%) | 1,572 (57.9%) | |
| Tumor clinical stage | 0.8034 | |||
| Other | 52 (1.0%) | 24 (0.9%) | 28 (1.0%) | |
| T1 | 4,333 (79.8%) | 2,180 (80.3%) | 2,153 (79.3%) | |
| T2 | 1,027 (18.9%) | 502 (18.5%) | 525 (19.3%) | |
| T3 | 18 (0.3%) | 9 (0.3%) | 9 (0.3%) | |
| Prostate-specific antigen | 0.2692 | |||
| <10 | 4,455 (82.0%) | 268 (9.9%) | 289 (10.6%) | |
| 10–20 | 557 (10.3%) | 2,250 (82.9%) | 2,205 (81.2%) | |
| >20 | 418 (7.7%) | 197 (7.3%) | 221 (8.1%) | |
| Gleason score | 0.0182 | |||
| 5 | 32 (0.6%) | 13 (0.5%) | 19 (0.7%) | |
| 6 | 3,020 (55.6%) | 1,558 (57.4%) | 1,462 (53.9%) | |
| 7 | 2,087 (38.4%) | 990 (36.5%) | 1,097 (40.4%) | |
| 8 | 214 (3.9%) | 107 (3.9%) | 107 (3.9%) | |
| 9 | 73 (1.3%) | 45 (1.7%) | 28 (1.0%) | |
| 10 | 4 (0.1%) | 2 (0.1%) | 2 (0.1%) | |
| Hormone therapy | 0.4834 | |||
| No | 4,925 (90.7%) | 2,455 (90.4%) | 2,470 (91.0%) | |
| Yes | 505 (9.3%) | 260 (9.6%) | 245 (9.0%) | |
| Dose level | <0.0001 | |||
| Low | 1,076 (19.8%) | 436 (16.1%) | 640 (23.6%) | |
| Intermediate | 3,903 (71.9%) | 2,039 (75.1%) | 1,864 (68.7%) | |
| High | 451 (8.3%) | 240 (8.8%) | 211 (7.8%) |